News | May 11, 2015

Twelve Late-Breaking Clinical Trials to be Presented at Heart Rhythm 2015

Key studies that will help advance electrophysiology at HRS

May 11, 2015 — The Heart Rhythm Society (HRS) has released the list of its 12 late-breaking electrophysiology (EP) clinical trials that will be presented at Heart Rhythm 2015, which takes place May 13-16, 2015 in Boston. 
 
Session I: Thursday, May 14, 1:30– 3 p.m. EDT in Ballroom West?
Impact of Remote Monitoring on Clinical Events and Healthcare Utilization: A nationwide assessment
VENTURE-AF: A Randomized Global Trial Evaluating Uninterrupted Rivaroxaban and Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Nonvalvular Atrial Fibrillation
Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients with Paroxysmal Atrial Fibrillation: The prospective, randomized controlled, non-inferiority FreezeAF Study
Botulinum Toxin Injection in Epicardial Fat Pads for Prevention of Atrial Fibrillation After Cardiac Surgery: One year follow up of randomized pilot study
Wireless LV Endocardial Stimulation for CRT: Primary results of the Safety and Performance of Electrodes implanted in the Left Ventricle (SELECT-LV) Study
The Evera MRI Study
 
Session II: Friday, May 15, 2015, 8–9:30 a.m. EDT in Ballroom West?
Performance of a Miniaturized Transcatheter Pacing System: First-in-human experience
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction: Safety and Efficacy in Patients with and without Chronic Resynchronization Therapy
Canadian Registry of Cardiac Implantable Electronic Device Outcomes: Phase 1 Riata Lead on Advisory (CREDO)
Clinical Safety of the Iforia ProMRI ICD System Subjected to 1.5T Cardiac or Thoracic Spine MRI
Effect of linear ablation in substrate-based AF: Results of the Substrate Modification with Ablation and Antiarrhythmic Drugs in Nonpermanent Atrial Fibrillation trial
Visually-Guided Laser Balloon (VGLB) Pulmonary Vein Isolation For The Treatment of Paroxysmal Atrial Fibrillation (PAF): Results Of The Prospective Multicenter Randomized Heartlight Study 
 
For more information: www.HRSonline.org
?
 

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init